EEG test to help understand and treat schizophrenia
News Oct 29, 2014
Researchers at University of California, San Diego School of Medicine have validated an EEG test to study and treat schizophrenia. The findings, published in two separate studies, offer a clinical test that could be used to help diagnose persons at risk for developing mental illness later in life, as well as an approach for measuring the efficacies of different treatment options.
One of the studies, reported online Oct. 23 in Schizophrenia Research, shows that schizophrenia patients don’t register subtle changes in reoccurring sounds as well as others and that this deficit can be measured by recording patterns of electrical brain activity obtained through electroencephalography (EEG).
The second, published online earlier this month in NeuroImage: Clinical, establishes a link between certain EEG tests and patients’ cognitive and psychosocial impairments, suggesting that the EEG test could be used to objectively measure the severity of a patient’s condition, and conversely that it might be possible to alleviate some of the symptoms of schizophrenia with specialized cognitive exercises designed to strengthen auditory processing.
“We are at the point where we can begin to bring simple EEG tests into the clinical setting to help patients,” said Gregory Light, PhD, associate professor of psychiatry and a co-author on both studies. “We think it may be possible to train some patients’ auditory circuits to function better. This could improve their quality of life, and possibly reduce common symptoms of schizophrenia such as hearing voices.”
In experiments, UC San Diego scientists and colleagues with the Consortium on the Genetics of Schizophrenia monitored volunteers’ electrical brain activity patterns as they listened to a sequence of beeps that occasionally included a discordant prolonged beep. The lengthier beeps were one-twentieth of a second longer than the standard beeps and occurred roughly 10 percent of the time.
A total of 1,790 people were tested at five sites nationwide as part of a National Institutes of Health-funded study to unravel the genetic basis of schizophrenia. Nine-hundred and sixty-six were schizophrenia patients; 824 were healthy control subjects.
The EEG data were analyzed for two auditory processing metrics. One is known as mismatch negativity (MMN). Measured in microvolts, MMN represents the difference between the brain’s response to the expected stream of beeps and its response to the singular, different ping. The other, called P3a, is a measure of the electrical energy emitted by the brain as it automatically shifts attention to the longer beep.
People with schizophrenia were consistently shown to have reduced MMN and P3a relative to those without the disease, suggesting they had a muted ability to detect and direct their attention to the discordant beep.
In the second study, researchers showed that measures of MMN and P3a were associated with the severity of a patient’s symptoms and their day-to-day real-world functioning.
Specifically, in a comparison of MMN and P3a measurements from 42 patients with schizophrenia and 47 non-psychiatric comparison subjects, scientists showed that differences in these auditory processing metrics accounted for approximately half of the variance in the severity of patients’ symptoms and their ability to perform tasks necessary for real-world functioning.
The two studies further validate the ability to measure MMN and P3a with only one EEG electrode placed on the front of the scalp, meaning that the EEG testing can be conducted outside of academic research laboratories.
Researchers plan to use their studies’ findings to try to improve the quality of life for patients at the Alpine Special Treatment Center, a mental health rehabilitation and long-term care facility in eastern San Diego County.
“Our goal is to see if we can help people improve their brain functioning by providing daily cognitive exercises that are designed to sharpen their sensory information processing,” said Light, who is also associate director of the VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC) at the Veterans Affairs San Diego Healthcare System. “We will then use EEGs to see if we can identify markers that predict which patients are most likely to benefit from this form of treatment.”
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Anthony J. Rissling, Makoto Miyakoshi, Catherine A. Sugar, David L. Braff, Scott Makeig, Gregory A. Light. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. NeuroImage: Clinical, Published Online October 1 2014. doi: 10.1016/j.nicl.2014.09.006
Gregory A. Light, Neal R. Swerdlow, Michael L. Thomas, Monica E. Calkins, Michael F. Green, Tiffany A. Greenwood, Raquel E. Gur, Ruben C. Gur, Laura C. Lazzeroni, Keith H. Nuechterlein, Marlena Pela, Allen D. Radant, Larry J. Seidman, Richard F. Sharp, Larry J. Siever, Jeremy M. Silverman, Joyce Sprock, William S. Stone, Catherine A. Sugar, Debby W. Tsuang, Ming T. Tsuang, David L. Braff, Bruce I. Turetsky. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophrenia Research, Published Online October 23 2014. doi: 10.1016/j.schres.2014.09.042
Catalyst Can Degrade Alzheimer's-Related Amyloid Peptide Under Near-Infrared LightNews
A new, biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Αβ) under near-infrared (NIR) light irradiation has been developed.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018